@inproceedings{oai:jaxa.repo.nii.ac.jp:00013107,
 author = {上村, 啓太 and 山, 智成 and 越智, ありさ and 河野, 尚平 and 中尾, 玲子 and 東端, 晃 and 平坂, 勝也 and 真板, 綾子 and 原田, 晃子 and 奥村, 裕司 and Kanmura, Keita and Yama, Tomonari and Ochi, Arisa and Kohno, Shohei and Nakao, Reiko and Higashibata, Akira and Hirasaka, Katsuya and Maita, Ayako and Harada, Akiko and Okumura, Yuushi},
 book = {宇宙利用シンポジウム: 第27回: 平成22年度, Space Utilization Research, Vol. 27 2011: Proceedings of The Twenty-seventh Space Utilization Symposium},
 month = {Mar},
 note = {第27回宇宙利用シンポジウム (2011年1月24日-25日, 宇宙航空研究開発機構宇宙科学研究所相模原キャンパス), 相模原市, 神奈川県, The Twenty-seventh Space Utilization Symposium (January 24-25, 2011. Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA)(ISAS)), Sagamihara, Kanagawa Japan, BACKGROUND: In muscle atrophy, Cbl-b ubiquitin ligase interacts with and degraded IGF-1 signaling intermediate IRS-1. This study aimed to inhibit Cbl-b-mediated IRS-1 ubiquitination and degradation by soy glycinin. METHODS: We used denervated mice fed soy glycinin diet, and examined the influence ofmuscle atrophy. RESULTS: Intake of soy glycinin prevented reduction of muscle wet weight and myofiber size. Furthermore, as a result in analysis of the effect to protection of IGF-1 pathway, the degradation and theubiquitination of IRS-1 were inhibited. In addition, elevation of gene expression of MAFbx/atrogin-1 and MuRF-1, activated by the loss of IRS-1, decresed significantly. CONCLUSIONS: This study suggested that soy glycinin protein contains inhibitory peptides against Cbl-b ubiqutin ligase. Soy glycinin peptide may provide new therapeutic applications for the prevention or treatment of muscle atrophy., 著者人数: 12人, Number of authors: 12, 資料番号: AA0065129047},
 pages = {127--128},
 publisher = {宇宙航空研究開発機構宇宙科学研究所 (JAXA)(ISAS), Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA)(ISAS)},
 title = {廃用性筋萎縮に有効な食材の開発とMyolab宇宙実験の速報},
 volume = {27},
 year = {2011}
}